1 / 1

Multiple Myeloma Market

In 2017, the total incident cases of Multiple Myeloma in 8MM was 85,971. The incident cases of Multiple Myeloma in the United States was found to be 30,271 in 2017. <br><br>The market size of Multiple Myeloma in 8MM was USD 14,111 million in 2017.<br><br>Increasing incidence rate, high adoption rate of newer therapies and an increase in the Geriatric Population are some of the key market drivers for Multiple Myeloma. <br><br>The key players in the Multiple Myeloma Market includes GlaxoSmithKline, Bristol-Myers Squibb, Bluebird bio, AbbVie, Roche, Janssen Biotech, Nanjing Legend Biotech, Oncopeptides AB, Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Celgene, RAPA Therapeutics, Pfizer, Cellectar Biosciences, BioLineRx, Aduro Biotech, ExCellThera, Takeda, Glenmark, Poseida Therapeutics, Amgen, Precision BioSciences, Juno Therapeutics, Molecular Partners AG, Cartesian Therapeutics, AstraZeneca, MorphoSys AG, I-Mab Biopharma and Chipscreen Biosciences. <br><br>For more detailed information on Multiple Myeloma Market, visit: https://www.delveinsight.com/report-store/multiple-myeloma-market<br><br>

Télécharger la présentation

Multiple Myeloma Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


    More Related